An Overview of Ertugliflozin and Dapagliflozin in The Treatment of Diabetes Mellitus

SGLT2 inhibitors are a class of oral drugs that have had little efficacy in treating type 2 diabetes. Ertugliflozin and Dapagliflozin is a novel pharmaceutical treatment for type 2 diabetes patients and a fervent member of the sodium-glucose cotransporter-2 (SGLT2) family. Its primary objective is to reduce the risk of cardiovascular issues related to kidneys, the microvascular system, the macro vascular system, and diabetic mellitus (DM). It works by increasing the excretion of glucose in the urine rather than requiring insulin. These drugs’ direct effects on the kidneys represent a new paradigm in medical care. Scientific research has demonstrated that the usage of SGLT-2 inhibitors can lower the risk of cardiovascular disease (CVD) in India, but hypoglycemia is a minor problem. It’s important to understand how Ertugliflozin impacts the kidneys. In situations where stricter blood sugar control is required, the FDA advises raising the beginning dose from 5 mg once daily to 15 mg once daily, if the drug is well tolerated. Hypovolemia and urinary tract infections are two of ertugflozin’s most frequent side effects. Because of its synergistic action, Ertugliflozin can benefit individuals with type 2 diabetes when taken with other medications. The sodium glucose otransporte, which in found in the proximal nehron and is in charge of reintroducing filtered glucose into the bloodstream, is inhibited by it. By blocking this cotransporter, glucose recovery dereased, glucose excretion is increased, and hyperglycemia is decreased. The literature on Erugliflozin and Dapagliflozin’s action, effectiveness and clinical application is reviewed here